Trial Profile
UCDCC#270: A Pilot Study of Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients Previously Treated With a PD-1 Inhibitor
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Aug 2022 Results assessing safety and efficacy data of of avelumab and stereotactic ablative radiotherapy in non-responding and progressing non-small cell lung cancer, presented at the 2022 World Conference on Lung Cancer.
- 19 Oct 2021 Status changed from recruiting to completed.
- 06 Jul 2020 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.